MetaVia DA-1726 48mg cohort achieves 9.1% weight loss at Day 54; vanoglipel combo shows synergy in MASH/T2D

MetaVia Inc.

DA-1726 Phase 1 48mg cohort: 9.1% mean weight loss at Day 54 (p<0.05 vs placebo), no plateau observed.
Waist circumference reduced by 9.8 cm at Day 54; BMI reduced by 3.4 kg/m².
Vanoglipel + resmetirom in MASH mouse model: 23.6% weight loss vs control, ALT reduction 83.5%.
Vanoglipel + metformin in T2D model: 16.3% weight loss, 28.7% non-fasting glucose reduction.
Phase 1 Part 3 titration studies for higher-dose DA-1726 ongoing; results expected Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.